Literature DB >> 32030746

Distinct clinical phenotype and genetic testing strategy for Lynch syndrome in China based on a large colorectal cancer cohort.

Lin Dong1, Xianglan Jin2, Wenmiao Wang1, Qiurong Ye3, Weihua Li1, Susheng Shi1, Lei Guo1, Jianming Ying1, Shuangmei Zou1.   

Abstract

Lynch syndrome (LS) is the most common hereditary colorectal cancer (CRC) predisposition syndrome. We performed a large-scale study to assess a screening strategy for identifying LS in Chinese CRC patients in routine clinical testing. A total of 4,195 eligible CRCs were universally screened. Then, 8.7% of CRCs were detected with dMMR. The incidence of LS was 2.7% (115 of 4,195) in this cohort; among patients over 70 years of age, only 0.3% (2 of 678) were diagnosed as LS. Then, 17.4% of LS cases showed large genomic deletions/duplications. LS probands developed CRCs predominantly at proximal colon location. The frequency of BRAF V600E mutation among Chinese CRCs was significantly lower than that among Western populations, and MLH1 promoter methylation significantly improved the efficiency of genetic screening for LS among MLH1-deficient patients. A comprehensive molecular testing strategy that includes detection of large genomic rearrangements is imperative for the diagnosis of LS. Among CRC patients aged 70 years or younger, a selective strategy for LS screening might be considered for routine clinical testing.
© 2020 UICC.

Entities:  

Keywords:  DNA mismatch repair; Lynch syndrome; cancer susceptibility; colorectal cancer; genetic testing

Year:  2020        PMID: 32030746     DOI: 10.1002/ijc.32914

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

Review 1.  Overview on population screening for carriers with germline mutations in mismatch repair (MMR) genes in China.

Authors:  Min Zhang; Tianhui Chen
Journal:  Hered Cancer Clin Pract       Date:  2021-05-01       Impact factor: 2.164

2.  Classification and genetic counselling for a novel splicing mutation of the MLH1 intron associated with Lynch syndrome in colorectal cancer.

Authors:  Ling-Ling Wang; Shuang-Mei Zou; Lin Dong; Ming Yang; Dan Qi; Zhao Lu; Jia-Nan Chen; Shi-Wen Mei; Zhi-Xun Zhao; Xu Guan; Zheng Jiang; Qian Liu; Zheng Liu; Xi-Shan Wang
Journal:  Gastroenterol Rep (Oxf)       Date:  2021-09-06

3.  Evaluating the role of IDO1 macrophages in immunotherapy using scRNA-seq and bulk-seq in colorectal cancer.

Authors:  Xingwu Liu; Guanyu Yan; Boyang Xu; Han Yu; Yue An; Mingjun Sun
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

4.  Cytoplasmic MSH2 Related to Genomic Deletions in the MSH2/EPCAM Genes in Colorectal Cancer Patients With Suspected Lynch Syndrome.

Authors:  Lin Dong; Shuangmei Zou; Xianglan Jin; Haizhen Lu; Ye Zhang; Lei Guo; Jianqiang Cai; Jianming Ying
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

5.  Germline mutational profile of Chinese patients under 70 years old with colorectal cancer.

Authors:  Teng-Jia Jiang; Fang Wang; Ying-Nan Wang; Jia-Jia Hu; Pei-Rong Ding; Jun-Zhong Lin; Zhi-Zhong Pan; Gong Chen; Jian-Yong Shao; Rui-Hua Xu; Qi Zhao; Feng Wang
Journal:  Cancer Commun (Lond)       Date:  2020-09-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.